We’re excited to share some promising results from a recent clinical trial that holds great promise for treating Type 1 diabetes.
This ground-breaking research was presented at the American Diabetes Association‘s 83rd Scientific Sessions on June 23, 2023. The study involved six patients who were administered varying doses of stem cell-derived beta cells. The results were nothing short of remarkable.
All six patients demonstrated improved glycemic control and reduced or even eliminated their insulin use. The beta cells functioned as expected, producing insulin and positive C-peptide levels in all patients.
The most exciting part? Two patients, after one year of follow-up, achieved insulin independence. This means they no longer require insulin injections to maintain their blood sugar levels. Furthermore, both patients met the study’s primary efficacy endpoint, which was the elimination of severe hypoglycemic events (SHEs) and a reduction of HbA1c (<7.0% or a decrease of at least 1% compared to baseline).
Our Chief Scientific Officer, Dr Lesley Ann Martin, shared her insights on these findings, “These clinical trial results are a testament to the immense potential of stem cells. At Cells4Life, we are committed to unlocking this potential, and these findings perfectly align with our mission. This milestone brings us one step closer to actualizing a future where conditions like Type 1 diabetes can be effectively treated, if not cured.”
At Cells4Life, we’re proud to be at the forefront of stem cell preservation in the UK, offering families the highest quality of stem cell storage thanks to our patented cryopreservation technology. Please follow our blog to stay updated on the latest developments in stem cell research.
Reference:
FIND OUT MORE, REQUEST YOUR WELCOME PACK TODAY
All you need to know to make an informed decision.
Provide your contact details to request:
– Complete Welcome Pack and Parent’s Guide
– Information via email
– Contact from our specialist advisors
